ARTICLE | Clinical News
Inovio gains on HIV vaccine data
May 24, 2017 10:48 PM UTC
Inovio Pharmaceuticals Inc. (NASDAQ:INO) gained $1.55 (22%) to $8.68 on Wednesday after it said data from a Phase I study in healthy volunteers showed that HIV vaccine Pennvax-GP produced "amongst the highest overall levels" of cellular and antibody immune response rates ever reported in human trials.
Pennvax-GP is a DNA vaccine targeting HIV env A, env C, gag polyprotein and pol, with coverage of HIV clades A, B and C. Inovio is developing the vaccine in collaboration with NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccines Trials Network (HVTN). NIAID funded the study...
BCIQ Company Profiles